The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997–2010: evidence from longitudinal, disease-level data
The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997–2010: evidence from longitudinal, disease-level data
复制标题
1997-2010 年瑞典制药创新对寿命和医疗支出的影响：来自纵向疾病水平数据的证据
DOI：
--
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
B. Pettersson
中科院分区：
文献类型：
--
作者：
F. Lichtenberg;B. Pettersson
我们使用纵向的疾病水平数据来分析瑞典制药创新对寿命和医疗支出的影响，在1997-2010年期间，瑞典的平均死亡年龄增加了1.88岁。据估计，在此期间，制药创新使平均死亡年龄增加了0.60岁。这些估计表明，寿命取决于治疗疾病的药物数量，而不是药物类别的数量。药物创新也降低了医院的利用率；估计数表明，一种疾病商业化药物数量的增加减少了8年后因该疾病住院的天数，这主要是由于它对出院人数的影响。据估计，从引进新药中获得的每生命年的成本，只占领先经济学家对预期寿命增加1年的价值估计的一小部分。
We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997–2010. Pharmaceutical innovation is estimated to have increased mean age at death by 0.60 years during the period. The estimates indicate that longevity depends on the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital utilization; the estimates indicate that an increase in the number of drugs commercialized for a disease reduces the number of hospital days due to the disease 8 years later, primarily due to its effect on the number of hospital discharges. The cost per life-year gained from the introduction of new drugs is estimated to be a small fraction of leading economists’ estimates of the value of a 1-year increase in life expectancy.